Prognostic classification and risk assessment in myelodysplastic syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 2, 2010, Pages 459-468

  Cazzola, Mario ^a   Malcovati, Luca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acute myeloid leukemia; Anemia; Myelodysplastic syndrome; Prognosis; Transfusion

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; HEMOPOIETIC GROWTH FACTOR; LENALIDOMIDE; PROTEIN TET2; THYMOCYTE ANTIBODY; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD ANALYSIS; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CHROMOSOME 4Q; COMORBIDITY; CYTOGENETICS; DISEASE CLASSIFICATION; DYNAMICS; HUMAN; KARYOTYPE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SOCIAL SUPPORT; SOMATIC MUTATION; STRATEGIC PLANNING; SURVIVAL; WATCHFUL WAITING; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; ANEMIA; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; BONE MARROW; CHROMOSOME ABERRATIONS; COMORBIDITY; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HEART FAILURE; HUMANS; IRON OVERLOAD; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MODELS, THEORETICAL; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; WORLD HEALTH ORGANIZATION;

EID: 77950539091     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.02.005     Document Type: Review

References (34)

1. Cazzola M., Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005, 352:536.
2. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 1872, 361:2009.
3. Cazzola M., Malcovati L. Risk-adapted treatment of myelodysplastic syndromes. Hematology Education 2009, 3:181.
4. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189.
5. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292.
6. Brunning R.D., Orazi A., Germing U., et al. Myelodysplastic syndromes/neoplasms, overview. WHO classification of tumours of hamatopoietic and lymphoid tissues 2008, 88. IARC, Lyon (France). S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
7. Bennett J.M., Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica 2009, 94:264.
8. Della Porta M.G., Malcovati L., Boveri E., et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009, 27:754.
9. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079.
10. Sanz G.F., Sanz M.A., Greenberg P.L. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998, 83:358.
11. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937.
12. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594.
13. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007, 31(Suppl 3):S2.
14. Kao J.M., McMillan A., Greenberg P.L. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008, 83:765.
15. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008, 52:818.
16. Cazzola M., Barosi G., Gobbi P.G., et al. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988, 71:305.
17. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91:1588.
18. Schafer A.I., Cheron R.G., Dluhy R., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981, 304:319.
19. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503.
20. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579.
21. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895.
22. Kantarjian H., O'Brien S., Ravandi F., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113:1351.
23. National Cancer Institute Surveillance EaERSR-A-AIRB, Bethesda, Maryland, National Cancer Institute Available at:, Accessed October, 2009. http://www.seer.cancer.gov.
24. Zipperer E., Pelz D., Nachtkamp K., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94:729.
25. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912.
26. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25:4246.
27. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289.
28. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838.
29. Kosmider O., Gelsi-Boyer V., Cheok M., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285.
30. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94:1676.
31. Orazi A., Bennet J.M., Germing U., et al. Chronic myelomonocytic leukaemia. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 76. IARC, Lyon (France). S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
32. Malcovati L., Della Porta M.G., Pietra D., et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009, 114:3538.
33. Alessandrino E.P., Amadori S., Barosi G., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002, 87:1286.
34. Bowen D., Culligan D., Jowitt S., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187.